Niraparib oral capsule clinical trials

SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy

This study looks at combining targeted radiotherapy (SBRT) with an ovarian cancer drug (niraparib) for women whose cancer has shown small areas of growth or comeback after previous treatment with a PARP inhibitor. It aims to see if this combination helps manage the cancer.